CoChat

Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction

Open access
Marabotti, Claudio · 2022 · Expert Review of Vaccines

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.

Abstract

Over the last few months, there has been a passionate debate within the scientific community on the risks and the benefits of the vaccines against COVID-19 disease. Reporting relative risk reductio...

Overview

CoChat Summary

TL;DR

This editorial argues that COVID-19 vaccine results should be reported using both relative risk reduction (RRR) and absolute risk reduction (ARR), because the two measures differ by orders of magnitude and can lead to different risk/benefit conclusions. The author concludes that RRR better expresses the intrinsic protective efficacy of a vaccine, while ARR (and its derivative NNV) is time- and baseline-risk-dependent and better suited to decision makers comparing vaccination effectiveness across populations.

Key findings

  • The 95% RRR reported for BNT162b2 (Pfizer-BioNTech) in its phase 3 trial corresponds to an ARR of only 0.85%, and an NNV of 119.
  • ARR and NNV are time-dependent: 5–6 month updates on BNT162b2 and mRNA-1273 (Moderna-NIH) showed ARR increasing to 3.7% and 4.9%, corresponding to NNVs of 27 and 21, respectively.
  • By comparison, polypill primary prevention had an NNT of 36–57 to prevent an acute cardiovascular event over 5 years (a period ~30 times longer than COVID-19 phase 3 studies); assuming an approximately constant slope of event-free survival curves, the author estimates a first-months NNT of roughly 1000, far higher than the NNV of 119 for BNT162b2.
  • ARR is not an intrinsic property of a vaccine but a predictor of real-world effectiveness resulting from the interaction between vaccine efficacy (RRR) and baseline population risk; the higher the viral circulation, the higher the ARR.

Methods

  • Design: editorial/commentary (Expert Review of Vaccines, pages 873–875); no new primary data collected.
  • Data: narrative synthesis of published phase 3 COVID-19 vaccine trials (BNT162b2, mRNA-1273, AZD1222, Ad26.COV2.S, rAd26/rAd5, NVX-CoV2373, CoronaVac, inactivated vaccines), influenza vaccine literature, the Seven Countries Study, and polypill cardiovascular prevention studies.
  • Analysis: conceptual comparison of RRR versus ARR/NNV, including a hypothetical worked example (Figure 1) of a vaccine with 75% RRR showing ARR of 12% versus 24% depending on baseline risk and follow-up duration.

Limitations

  • The author explicitly states the polypill comparison is an "oversimplified model," and notes that factors such as progressive reduction in vulnerable subjects, immunity decline, and emerging escape variants can modify vaccine effectiveness over time.
  • The author states that the unusual conditions under which COVID-19 vaccines were tested (especially social distancing, which cannot be maintained long-term) may make ARR an unreliable "effectiveness predictor" of vaccination at population level.
  • Evident from the text: this is a non-systematic editorial without formal search strategy, meta-analysis, or quantitative synthesis; numerical comparisons rely on cited trials and a hypothetical figure rather than new empirical analysis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1080/14760584.2022.2067531

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Image 1
From the PDF
Image 2
From the PDF
Figure 1 Schematic representation of the influences of baseline risk and follow up duration on ARR in a hypothetical study on the effects of a vaccine with a 75% RRR. A: Population at low risk and short observation. RRR 75% corresponds to an ARR of 12% (16% of cases in unvaccinated subjects vs. 4% in vaccinated subjects). B: Extending follow up in the same sample and at steady risk will increase the number of infected subjects (32% in unvaccinated subjects vs. 8% in vaccinated subjects). RRR 75% will therefore correspond to an ARR of 24%. C: Population at higher risk and short observation. RRR 75% corresponds to an ARR of 24%. (32% of cases in unvaccinated subjects vs. 8% in vaccinated subjects).
Figure 1 Schematic representation of the influences of baseline risk and follow up duration on ARR in a hypothetical study on the effects of a vaccine with a 75% RRR. A: Population at low risk and short observation. RRR 75% corresponds to an ARR of 12% (16% of cases in unvaccinated subjects vs. 4% in vaccinated subjects). B: Extending follow up in the same sample and at steady risk will increase the number of infected subjects (32% in unvaccinated subjects vs. 8% in vaccinated subjects). RRR 75% will therefore correspond to an ARR of 24%. C: Population at higher risk and short observation. RRR 75% corresponds to an ARR of 24%. (32% of cases in unvaccinated subjects vs. 8% in vaccinated subjects).From the PDF

Verification

Claims the paper makes

0 Valid · 0 Not valid · 12 Not checked · 10 Own results and interpretations

11 more claims

Create a free account to see all 22 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 5
  • Probably not a substantial claim. 1

Create a free account to see these claims.

Citations

Cites

Show all 17 references

Cited by

See all 13

Metadata

Authors
Marabotti, C.
Affiliations
Azienda USL Toscana Nord Ovest (IT)
Corresponding author
Marabotti, Claudio
Venue
Expert Review of Vaccines
Published
2022-04-19
Volume
21
Issue
7
Pages
873-875
ISSN
  • 1476-0584 (ISSN-L)
  • 1744-8395
OpenAlex
W4223996786
Cited by
13
References
15
Citations by year
2025: 2 · 2024: 2 · 2023: 2 · 2022: 7
Type
journal article
Language
en
Open access
Locations
  • Expert Review of Vaccines (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
London School of Hygiene and Tropical Medicine
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords
COVID-19 vaccines, vaccine efficacy, vaccine effectiveness, absolute risk reduction, relative risk reduction, risk-benefit assessment
MeSH terms
COVID-19, COVID-19 Vaccines, Humans, Influenza, Human, Influenza Vaccines, Risk, Vaccination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction. https://app.cochat.ai/papers/10.1080/14760584.2022.2067531
The paper
Marabotti, C. (2022). Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction. Expert Review of Vaccines. https://doi.org/10.1080/14760584.2022.2067531

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.